A Phase 3 interventional study of D/C/F/TAF and Boosted Protease Inhibitor (bPI) in Human Immunodeficiency Virus Type 1, sponsored by Janssen R&D Ireland. Completed at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-09.
Sponsored by Janssen R&D Ireland (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid [HIV-1 RNA] concentrations less than [\<] 50 copies per milliliter [copies/mL]) HIV-1 infected participants.
This is a randomized (study medication assigned to participants by chance), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), open-label (participants and researchers are aware about the treatment, participants are receiving), multicenter (when more than 1 hospital or medical school team work on a medical research study), study in virologically-suppressed, HIV-1 infected adult participants. The study will include a Screening Period of approximately 30 days (up to maximum 6 weeks), a controlled Treatment Period of 48 weeks, an Extension Phase of 48 weeks. All eligible participants will be randomly assigned to receive either current treatment regimen - a bPI (limited to DRV with low-dose ritonavir [rtv] or COBI, atazanavir [ATV] with rtv or COBI, or lopinavir [LPV] with rtv) combined with FTC/TDF, or experimental treatment regimen - D/C/F/TAF once-daily single-tablet for 48 weeks. After completion of week 48, participants assigned to the experimental treatment will continue with D/C/F/TAF in the extension phase up to week 96 . Participants who continued their current regimen will receive the experimental treatment (if all criteria are fulfilled) at week 52 up to week 96. As from Week 96, all participants will be given the option to continue D/C/F/TAF treatment, if they wish and if they continue to benefit from it until D/C/F/TAF becomes commercially available and is reimbursed, or can be accessed through another source in the country where he/she is living,or until the sponsor terminates clinical development. A bone investigation substudy will be performed at selected study sites, to assess bone biomarkers and energy x-ray absorptiometry (DXA) scans, in approximately 300 participants (200 in the D/C/F/TAF treatment arm versus 100 in the control arm) who provide informed consent for the substudy.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 1,149 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Janssen R&D Ireland is the lead sponsor of 32 studies on the registry; none are open to participants now.
First submitted after Janssen R&D Ireland became part of Johnson & Johnson.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
Drug: D/C/F/TAF
Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
Drug: Boosted Protease Inhibitor (bPI) · Drug: FTC/TDF
Drug page: Tenofovir alafenamide
Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48
Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (\>=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
Time frame: Through Week 48
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
Time frame: Through 48 Weeks
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
Time frame: Through 48 Weeks
Percentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at week 48.
Time frame: Baseline up to Week 48
Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Through Week 48
An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
Time frame: Up to Week 48
Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48
Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.
Time frame: Baseline and Weeks 24 and 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48
Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min).
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48
Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993age.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48
Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996age (\*0.932 if female).
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48
Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48
Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.
Time frame: Baseline, Weeks 24 and 48
Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48
Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (<)20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA \<20/50/200 copies/mL (observed case).
Time frame: Week 48
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.
Time frame: Week 48
Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48
Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Percentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 48
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).
Time frame: Through Week 48
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 48
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).
Time frame: Through Week 48
Number of Participants With Resistance to Study Drug
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value \>=400 copies/mL or who discontinued with last HIV-1 RNA \>=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.
Time frame: Up to Week 48
Predose (Trough) Plasma Concentration (C0h) of Darunavir
Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.
Time frame: Predose at Weeks 2, 4, 8, 12, 24, 36, and 48
Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48
Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48
Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48
Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48
Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48
Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values \>= -1.0 were considered normal, T-score values \< -1.0 to -2.5 indicate osteopenia and T-score values \< -2.5 indicate osteoporosis.
Time frame: Baseline, Weeks 24 and 48
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 96
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 96
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=50 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=50copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 96
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=200 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=200 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates
Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at Week 96.
Time frame: Baseline to Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as having last available HIV-1 RNA \<20/50/200 copies/mL (observed case).
Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the TLOVR Algorithm
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.
Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Percentage of Participants With Virologic Failure Based on HIV-1 RNA >=20, >=50, and >=200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach
Percentage of participants with virologic failure based on HIV-1 RNA \>=20, \>=50, and \>=200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic failure was defined by the FDA snapshot approach as having last available HIV-1 RNA \>=20/50/200 copies/mL at Week 96; virologic failure - leading to discontinuation; virologic failure - discontinued due to other reason and last available HIV-1 RNA \>=20/50/200 copies/mL.
Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Change From Reference in CD4+ Cell Count at Week 96
Change from reference in CD4+ cell count was assessed at Week 96. The change from reference in CD4+ count at a given time point is defined as: CD4+ at a given time point minus reference CD4+. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF (Comprising 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52])
Number of Participants With Resistance to Study Drug Through Week 96
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound in case they had HIV-1 RNA values \>=400 copies/mL at failure or at later time points, including participants who discontinued with last HIV-1 RNA \>=400 copies/mL. Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Number of participants who developed resistance to any of the study drug (DRV, FTC, and TFV/TAF) were reported.
Time frame: Through Week 96 (D/C/F/TAF arm), up to Week 48 (Control arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 96
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 96 (Approach 1).
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 96
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 96, whichever came sooner (Approach 2).
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Percentage of Participants Experiencing Grade 3 and Grade 4 AEs, SAEs, and Premature Discontinuation Due to AEs Through Week 96
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Change From Reference in Serum Creatinine Levels at Week 96
Change from reference in serum creatinine levels at Week 96 was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96
Change from reference in eGFRcr (by Cockcroft-Gault formula) was assessed at Week 96. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96
Change from reference in eGFRcr (by CKD-EPI) was assessed at Week 96. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993\^age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993\^age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993\^age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993\^age. . For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96
Change from reference in eGFRcyst (by CKD-EPI) was assessed at Week 96. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996\^age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996\^age (\*0.932 if female). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UACR at Week 96
Change from reference in UACR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in URBPCR at Week 96
Change from reference in URBPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UPCR at Week 96
Change from reference in UPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UB2MGCR at Week 96
Change from reference in UB2MGCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in FEPO4 at Week 96
Percent change from reference in FEPO4 at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Levels of Serum P1NP at Week 96
Percent change from reference in serum P1NP levels at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Levels of Serum CTX at Week 96
Percent change from reference in serum CTX at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Levels of PTH at Week 96
Percent change from reference in PTH at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Levels of 25-OH Vitamin D at Week 96
Percent change from reference in 25-OH Vitamin D at Week 96 were reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Hip and Spine BMD at Week 96
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in BMD T-score of Hip and Spine at Week 96
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percentage of Participants With Non-Virologic Rebound by Kaplan-Meier Estimates
Virologic rebound is defined as participants who show confirmed HIV-1 RNA \>=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was \>=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented.
Time frame: Week 96 to end of extension (at every 6 months, up to 42 months)
Percentage of Participants With Non-Treatment Failure by Kaplan-Meier Estimates
Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral \[ARV\]).
Time frame: Week 96 to end of extension (up to 42 months)
Percentage of Participants With HIV RNA <50, <20, <200 Copies/mL Post Week 96 to End of Extension
Percentage of participants with HIV RNA \<50, \<20, \<200 copies/mL post Week 96 to end of extension were reported.
Time frame: Week 96 to end of extension (up to 42 months)
CD4+ Cell Count Post-Week 96 to End of Extension
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.
Time frame: Week 96 to end of extension (up to 42 months)
Percentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability and was calculated cumulative from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study from Week 96 to end of extension.
Time frame: Week 96 to end of extension (up to 42 months)
Percentage of Participants Experiencing Grade 3 and 4 AEs, Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Post-Week 96 to End of Extension
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From Week 96 to end of extension (up to 42 months)
| Milestone | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Started | 766 | 383 | 0 |
| Treated | 763 | 378 | 0 |
| Completed | 649 | 352 | 0 |
| Not completed | 117 | 31 | 0 |
| Withdrew: Lost to follow-up | 25 | 7 | 0 |
| Withdrew: Other | 19 | 4 | 0 |
| Withdrew: Withdrawal by subject | 32 | 10 | 0 |
| Withdrew: Adverse event | 24 | 4 | 0 |
| Withdrew: Non-compliance with study drug | 4 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Death | 4 | 0 | 0 |
| Withdrew: Randomized but not treated | 3 | 5 | 0 |
| Milestone | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Started | 0 | 0 | 352 |
| Completed | 0 | 0 | 314 |
| Not completed | 0 | 0 | 38 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 10 |
| Withdrew: Adverse event | 0 | 0 | 11 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 |
| Withdrew: Other | 0 | 0 | 8 |
Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (\>=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
| Percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48 | 2.5 (1.5 to 3.9) | 2.1 (0.9 to 4.1) |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks | 10.5 (8.4 to 12.9) | 11.4 (8.4 to 15.0) |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks | 0.4 (0.1 to 1.1) | 0.0 (NA to NA) |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at week 48.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates | 97.7 (96.4 to 98.6) | 97.8 (95.7 to 98.9) |
An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Grade 3 AEs | 5.6 | 6.3 |
| Grade 4 AEs | 1.2 | 1.9 |
| SAEs | 4.6 | 4.8 |
| Premature discontinuations due to AEs | 1.4 | 1.3 |
Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.
| micro mole per liter | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Change at Week 24 | 1.22 ± 0.358 | 0.88 ± 0.509 |
| Change at Week 48 | 1.27 ± 0.368 | 0.65 ± 0.530 |
Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min).
| milliliter per minute (mL/min) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Change at Week 24 | -0.38 ± 0.502 | 0.20 ± 0.715 |
| Change at Week 48 | -0.94 ± 0.492 | -0.20 ± 0.708 |
Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993age.
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Change at Week 24 | -1.67 ± 0.359 | -0.75 ± 0.510 |
| Change at Week 48 | -1.97 ± 0.369 | -0.88 ± 0.531 |
Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996age (\*0.932 if female).
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| eGFRcyst: Change at Week 24 | 0.21 ± 0.338 | -0.93 ± 0.483 |
| eGFRcyst: Change at Week 48 | -0.42 ± 0.360 | -1.76 ± 0.517 |
Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.
| milligram per gram (mg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| UACR: Baseline | 6.20 (1.4 to 632.1) | 7.14 (1.1 to 268.0) |
| UACR: Change at Week 24 | -0.78 (-185.4 to 422.2) | 0.44 (-238.5 to 145.0) |
| UACR: Change at Week 48 | -0.76 (-195.8 to 344.3) | 0.40 (-121.7 to 110.9) |
| UPCR: Baseline | 61.56 (16.9 to 1158.1) | 62.90 (14.7 to 870.9) |
| UPCR: Change at Week 24 | -14.63 (-509.6 to 734.6) | 0.07 (-359.9 to 400.8) |
| UPCR: Change at Week 48 | -22.25 (-520.1 to 386.6) | -7.37 (-368.7 to 432.3) |
Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.
| microgram per gram (mcg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| URBPCR: Baseline | 126.19 (20.3 to 116216.2) | 137.16 (12.9 to 73958.4) |
| URBPCR: Change at Week 24 | -30.27 (-69873.2 to 2004.4) | 7.76 (-6040.1 to 60740.4) |
| URBPCR: Change at Week 48 | -27.09 (-67540.0 to 1764.3) | 19.66 (-5778.3 to 65203.3) |
| UB2MGCR: Baseline | 156.85 (3.8 to 91216.2) | 172.25 (9.8 to 92740.1) |
| UB2MGCR: Change at Week 24 | -72.64 (-72264.6 to 13536.2) | 12.08 (-20084.8 to 58357.6) |
| UB2MGCR: Change at Week 48 | -67.02 (-72323.4 to 21190.2) | 20.24 (-22173.5 to 135576.9) |
Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.
| Percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percent change at Week 24 | 3.58 (-89.4 to 1940.4) | 8.55 (-78.5 to 281.8) |
| Percent change at Week 48 | 8.42 (-97.9 to 1430.3) | 8.57 (-76.3 to 452.7) |
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA \<20/50/200 copies/mL (observed case).
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| <20 copies/mL | 89.8 (87.4 to 91.8) | 88.4 (84.7 to 91.4) |
| <50 copies/mL | 94.9 (93.1 to 96.3) | 93.7 (90.7 to 95.9) |
| <200 copies/mL | 95.0 (93.2 to 96.5) | 94.2 (91.3 to 96.3) |
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| <20 copies/mL | 86.0 (83.3 to 88.4) | 83.6 (79.5 to 87.2) |
| <50 copies/mL | 93.7 (91.7 to 95.3) | 92.9 (89.8 to 95.2) |
| <200 copies/mL | 95.4 (93.7 to 96.8) | 94.7 (91.9 to 96.7) |
Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.
| Cells per cubic millimeter (cells/mm^3) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Baseline | 653.3 ± 9.12 | 641.7 ± 13.15 |
| Change at Week 24 | 14.3 ± 5.99 | 8.5 ± 7.76 |
| Change at Week 48 | 21.0 ± 5.97 | 9.1 ± 8.41 |
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).
| Percentage of Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 48 | 91.6 | 85.3 |
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 48 | 82.7 | 77.2 |
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value \>=400 copies/mL or who discontinued with last HIV-1 RNA \>=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.
| Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Number of Participants With Resistance to Study Drug | 1 | 3 |
Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.
| Nanogram per milliliter (ng/mL) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) |
|---|---|
| Week 2 | 1775.29 ± 1698.84 |
| Week 4 | 1732.00 ± 1389.44 |
| Week 8 | 1910.30 ± 1501.94 |
| Week 12 | 1643.38 ± 1328.41 |
| Week 24 | 2022.99 ± 1965.64 |
| Week 36 | 1806.37 ± 1669.43 |
| Week 48 | 1899.79 ± 1833.09 |
Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.
| Percent Change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| P1NP: Percent change at Week 24 | -22.971 ± 1.8818 | -0.027 ± 2.7325 |
| P1NP: Percent change at Week 48 | -26.752 ± 1.8960 | -3.751 ± 2.6988 |
| CTX: Percent change at Week 24 | -16.772 ± 2.2575 | 16.312 ± 3.8855 |
| CTX: Percent change at Week 48 | -10.517 ± 3.2325 | 5.433 ± 4.1118 |
Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.
| Percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percent change at Week 24 | -3.092 ± 2.5941 | 12.034 ± 4.1777 |
| Percent change at Week 48 | -4.510 ± 2.5375 | 9.436 ± 4.4784 |
Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.
| Percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Percent change at Week 24 | -3.0 ± 5.06 | 4.2 ± 6.13 |
| Percent change at Week 48 | 25.2 ± 5.51 | 24.9 ± 7.46 |
Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.
| Percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Spine BMD: Percent change at Week 24 | 1.55 ± 0.276 | 0.18 ± 0.342 |
| Spine BMD: Percent change at Week 48 | 2.06 ± 0.324 | 0.01 ± 0.391 |
| Hip BMD: Percent change at Week 24 | 0.91 ± 0.230 | 0.00 ± 0.279 |
| Hip BMD: Percent change at Week 48 | 1.62 ± 0.244 | -0.08 ± 0.288 |
Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values \>= -1.0 were considered normal, T-score values \< -1.0 to -2.5 indicate osteopenia and T-score values \< -2.5 indicate osteoporosis.
| Units on a scale | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) |
|---|---|---|
| Spine BMD T-score: Baseline | -0.713 ± 0.0850 | -0.467 ± 0.1260 |
| Spine BMD T-score: Change at Week 24 | 0.102 ± 0.0172 | -0.033 ± 0.0253 |
| Spine BMD T-score: Change at Week 48 | 0.132 ± 0.0217 | -0.063 ± 0.0264 |
| Hip BMD T-score: Baseline | -0.575 ± 0.0643 | -0.484 ± 0.0839 |
| Hip BMD T-score: Change at Week 24 | 0.037 ± 0.0108 | -0.024 ± 0.0144 |
| Hip BMD T-score: Change at Week 48 | 0.095 ± 0.0122 | -0.016 ± 0.0139 |
| Femoral Neck BMD T-score: Baseline | -0.782 ± 0.0625 | -0.699 ± 0.0899 |
| Femoral Neck BMD T-score: Change at Week 24 | 0.019 ± 0.0128 | -0.044 ± 0.0183 |
| Femoral Neck BMD T-score: Change at Week 48 | 0.039 ± 0.0146 | -0.039 ± 0.0214 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 96 | 13.8 (11.4 to 16.4) | 8.8 (6.1 to 12.3) |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=50 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=50copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 96 | 3.1 (2.0 to 4.6) | 2.3 (1.0 to 4.4) |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=200 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=200 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 96 | 0.5 (0.1 to 1.3) | 0.6 (0.1 to 2.0) |
Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at Week 96.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates | 96.7 (95.1 to 97.8) | 97.8 (95.4 to 98.9) |
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as having last available HIV-1 RNA \<20/50/200 copies/mL (observed case).
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| <20 copies/mL | 85.3 (82.6 to 87.8) | 89.8 (86.1 to 92.7) |
| <50 copies/mL | 90.7 (88.4 to 92.7) | 93.8 (90.7 to 96) |
| <200 copies/mL | 91.2 (89.0 to 93.1) | 95.5 (92.7 to 97.4) |
Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| <20 copies/mL | 79.6 (76.5 to 82.4) | 88.1 (84.2 to 91.3) |
| <50 copies/mL | 89.6 (87.3 to 91.7) | 94.3 (91.4 to 96.5) |
| <200 copies/mL | 91.7 (89.6 to 93.6) | 95.7 (93.1 to 97.6) |
Percentage of participants with virologic failure based on HIV-1 RNA \>=20, \>=50, and \>=200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic failure was defined by the FDA snapshot approach as having last available HIV-1 RNA \>=20/50/200 copies/mL at Week 96; virologic failure - leading to discontinuation; virologic failure - discontinued due to other reason and last available HIV-1 RNA \>=20/50/200 copies/mL.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| >=20 copies/mL | 6.8 (5.1 to 8.8) | 6.0 (3.7 to 9.0) |
| >=50 copies/mL | 1.2 (0.5 to 2.2) | 1.7 (0.6 to 3.7) |
| >=200 copies/mL | 0.3 (0.0 to 0.9) | 0 (NA to NA) |
Change from reference in CD4+ cell count was assessed at Week 96. The change from reference in CD4+ count at a given time point is defined as: CD4+ at a given time point minus reference CD4+. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| cells per cubic millimeter (cells/mm^3) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in CD4+ Cell Count at Week 96 | 32.07 ± 8.0 | 13.07 ± 10.7 |
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound in case they had HIV-1 RNA values \>=400 copies/mL at failure or at later time points, including participants who discontinued with last HIV-1 RNA \>=400 copies/mL. Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Number of participants who developed resistance to any of the study drug (DRV, FTC, and TFV/TAF) were reported.
| Participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| DRV resistance-associated mutations (RAMs) | 0 | 0 | 0 |
| TFV RAMs | 0 | 0 | 0 |
| FTC RAMs | 0 | 0 | 1 |
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 96 (Approach 1).
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 96 | 91.6 | 87.3 |
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 96, whichever came sooner (Approach 2).
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 96 | 82.8 | 80.9 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Grade 3 AEs | 10.5 | 6.3 |
| Grade 4 AEs | 2.4 | 1.1 |
| SAEs | 8.7 | 6.0 |
| Premature discontinuations due to AEs | 2.2 | 2.0 |
Change from reference in serum creatinine levels at Week 96 was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| micro mole per liter | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Serum Creatinine Levels at Week 96 | 0.0 (-35 to 44) | 0.0 (-45 to 29) |
Change from reference in eGFRcr (by Cockcroft-Gault formula) was assessed at Week 96. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| milliliter per minute (mL/min) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96 | -0.9 (-65 to 58) | 0.0 (-44 to 157) |
Change from reference in eGFRcr (by CKD-EPI) was assessed at Week 96. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993\^age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993\^age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993\^age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993\^age. . For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96 | -1.3 (-37 to 35) | -0.7 (-31 to 49) |
Change from reference in eGFRcyst (by CKD-EPI) was assessed at Week 96. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996\^age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996\^age (\*0.932 if female). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96 | -0.9 (-42 to 30) | 1.0 (-30 to 105) |
Change from reference in UACR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| milligram per gram (mg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UACR at Week 96 | -0.63 (-209.3 to 2019.7) | -0.93 (-234.6 to 13230.9) |
Change from reference in URBPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| microgram per gram (mcg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in URBPCR at Week 96 | -25.08 (-61980.5 to 1393.0) | -39.07 (-82240.7 to 869.9) |
Change from reference in UPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| milligram per gram (mg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UPCR at Week 96 | -22.23 (-533.3 to 2314.7) | -12.81 (-722.1 to 453.1) |
Change from reference in UB2MGCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| microgram per gram (mcg/g) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UB2MGCR at Week 96 | -68.22 (-71549.3 to 7433.1) | -110.31 (-152500.2 to 12288.4) |
Percent change from reference in FEPO4 at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in FEPO4 at Week 96 | 4.15 (-88.0 to 524.8) | -3.19 (-77.9 to 547.8) |
Percent change from reference in serum P1NP levels at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in Levels of Serum P1NP at Week 96 | -19.899 ± 2.2151 | -18.466 ± 3.1169 |
Percent change from reference in serum CTX at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in Levels of Serum CTX at Week 96 | -10.192 ± 3.0592 | -21.755 ± 3.4926 |
Percent change from reference in PTH at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in Levels of PTH at Week 96 | -17.171 ± 2.6774 | -20.466 ± 3.2559 |
Percent change from reference in 25-OH Vitamin D at Week 96 were reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in Levels of 25-OH Vitamin D at Week 96 | 24.6 ± 5.16 | -1.9 ± 3.33 |
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| percent change | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Hip region BMD-T score | 0.0173 ± 0.00217 | 0.0108 ± 0.00328 |
| Spine region BMD-T score | 0.0193 ± 0.00286 | 0.0279 ± 0.00381 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).
| units on a scale | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Hip region BMD | 0.122 ± 0.0154 | 0.077 ± 0.0230 |
| Spine region BMD | 0.176 ± 0.0259 | 0.255 ± 0.0339 |
Virologic rebound is defined as participants who show confirmed HIV-1 RNA \>=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was \>=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 | 100 (100 to 100) | 100 (100 to 100) |
| Week 96 + 6 months | 99.4 (98.4 to 99.8) | 100 (100 to 100) |
| Week 96 + 12 months | 98.0 (96.5 to 98.9) | 98.5 (96.0 to 99.4) |
| Week 96 + 18 months | 97.6 (95.9 to 98.6) | 98.1 (95.4 to 99.2) |
| Week 96 + 24 months | 97.1 (94.9 to 98.3) | 96.5 (92.3 to 98.4) |
| Week 96 + 30 months | 95.3 (91.3 to 97.5) | 96.5 (92.3 to 98.4) |
| Week 96 + 36 months | 92.4 (83 to 96.7) | 96.5 (92.3 to 98.4) |
| Week 96 + 42 months | 92.4 (83.0 to 96.7) | — |
Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral \[ARV\]).
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 | 100 (100 to 100) | 100 (100 to 100) |
| Week 96 + 6 months | 98.1 (96.7 to 98.9) | 98.5 (96.3 to 99.4) |
| Week 96 + 12 months | 94.3 (92.2 to 95.9) | 95.4 (92.3 to 97.2) |
| Week 96 + 18 months | 91.6 (89.0 to 93.6) | 92.2 (88.3 to 94.8) |
| Week 96 + 24 months | 89.4 (86.1 to 91.9) | 89.7 (85.0 to 93.0) |
| Week 96 + 30 months | 87.0 (82.7 to 90.4) | 88.1 (82.0 to 92.2) |
| Week 96 + 36 months | 84.9 (78.2 to 89.6) | 82.6 (67.4 to 91.1) |
| Week 96 + 42 months | 81.7 (71.9 to 88.4) | — |
Percentage of participants with HIV RNA \<50, \<20, \<200 copies/mL post Week 96 to end of extension were reported.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 + 6 months (<50 copies/mL) | 97.8 (96.4 to 98.8) | 97.9 (95.7 to 99.2) |
| Week 96 + 12 months (<50 copies/mL) | 98.4 (97.0 to 99.2) | 97.4 (94.8 to 98.8) |
| Week 96 + 18 months (<50 copies/mL) | 99.6 (98.4 to 99.9) | 98.7 (96.2 to 99.7) |
| Week 96 + 24 months (<50 copies/mL) | 99.3 (97.4 to 99.9) | 98.5 (94.7 to 99.8) |
| Week 96 + 30 months (<50 copies/mL) | 99.3 (95.9 to 100) | 100 (94.4 to 100) |
| Week 96 + 36 months (<50 copies/mL) | 98.1 (89.7 to 100) | 100 (86.8 to 100) |
| Week 96 + 42 months (<50 copies/mL) | 100 (79.4 to 100) | 100 (59.0 to 100) |
| Week 96 + 6 months (<200 copies/mL) | 99.1 (98.1 to 99.7) | 99.7 (98.3 to 100) |
| Week 96 + 12 months (<200 copies/mL) | 99.3 (98.3 to 99.8) | 98.7 (96.6 to 99.6) |
| Week 96 + 18 months (<200 copies/mL) | 100 (99.2 to 100) | 99.1 (96.8 to 99.9) |
| Week 96 + 24 months (<200 copies/mL) | 99.6 (98.0 to 100) | 99.3 (95.9 to 100) |
| Week 96 + 30 months (<200 copies/mL) | 100 (97.3 to 100) | 100 (94.4 to 100) |
| Week 96 + 36 months (<200 copies/mL) | 100 (93.2 to 100) | 100 (86.8 to 100) |
| Week 96 + 42 months (<200 copies/mL) | 100 (79.4 to 100) | 100 (59 to 100) |
| Week 96 + 6 months (<20 copies/mL) | 91.4 (89.1 to 93.4) | 93.4 (90.2 to 95.8) |
| Week 96 + 12 months (<20 copies/mL) | 93.9 (91.7 to 95.7) | 91.4 (87.6 to 94.3) |
| Week 96 + 18 months (<20 copies/mL) | 96.1 (93.9 to 97.7) | 92.9 (88.7 to 95.9) |
| Week 96 + 24 months (<20 copies/mL) | 96.1 (93.1 to 98.0) | 95.5 (90.5 to 98.3) |
| Week 96 + 30 months (<20 copies/mL) | 95.6 (90.6 to 98.4) | 92.2 (82.7 to 97.4) |
| Week 96 + 36 months (<20 copies/mL) | 94.2 (84.1 to 98.8) | 96.2 (80.4 to 99.9) |
| Week 96 + 42 months (<20 copies/mL) | 93.8 (69.8 to 99.8) | 100 (59 to 100) |
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.
| cells/mm^3 | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 + 6 months | 706.4 ± 10.51 | 681.3 ± 14.99 |
| Week 96 + 12 months | 707.6 ± 11.93 | 676.2 ± 14.57 |
| Week 96 + 18 months | 713.3 ± 12.16 | 686.1 ± 17.05 |
| Week 96 + 24 months | 712.7 ± 15.98 | 686.4 ± 21.20 |
| Week 96 + 30 months | 730.4 ± 23.24 | 685.8 ± 28.61 |
| Week 96 + 36 months | 732.0 ± 33.10 | 733.3 ± 54.73 |
| Week 96 + 42 months | 714.3 ± 56.26 | 705.6 ± 112.99 |
Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability and was calculated cumulative from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study from Week 96 to end of extension.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension | 89.5 | 89.4 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Grade 3 AEs | 5.7 | 5.0 |
| Grade 4 AEs | 2.1 | 1.5 |
| SAEs | 7.3 | 7.7 |
| Premature discontinuations due to AEs | 1.1 | 2.1 |
Collected over Up to 5 years and 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 4/763 (0.5%) | 114/763 (14.9%) | 584/763 (76.5%) |
| Control (Baseline to Switch) | 0/378 (0%) | 18/378 (4.8%) | 222/378 (58.7%) |
| Switch to D/C/F/TAF Group | 1/352 (0.3%) | 42/352 (11.9%) | 213/352 (60.5%) |
| Event | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Control (Baseline to Switch) | Switch to D/C/F/TAF Group |
|---|---|---|---|
| PneumoniaInfections and infestations | 10/763 | 0/378 | 3/352 |
| AppendicitisInfections and infestations | 2/763 | 0/378 | 3/352 |
| DepressionPsychiatric disorders | 1/763 | 0/378 | 3/352 |
| Suicidal ideationPsychiatric disorders | 1/763 | 1/378 | 3/352 |
| Non-cardiac chest painGeneral disorders | 2/763 | 0/378 | 2/352 |
| CellulitisInfections and infestations | 2/763 | 1/378 | 2/352 |
| SepsisInfections and infestations | 0/763 | 0/378 | 2/352 |
| Myocardial infarctionCardiac disorders | 4/763 | 1/378 | 1/352 |
| DiverticulitisInfections and infestations | 4/763 | 0/378 | 0/352 |
| GastroenteritisInfections and infestations | 4/763 | 0/378 | 0/352 |
| Event | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Control (Baseline to Switch) | Switch to D/C/F/TAF Group |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 163/763 | 39/378 | 56/352 |
| NasopharyngitisInfections and infestations | 144/763 | 42/378 | 42/352 |
| Back painMusculoskeletal and connective tissue disorders | 107/763 | 23/378 | 31/352 |
| DiarrhoeaGastrointestinal disorders | 104/763 | 18/378 | 40/352 |
| HeadacheNervous system disorders | 93/763 | 18/378 | 29/352 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 84/763 | 9/378 | 22/352 |
| CoughRespiratory, thoracic and mediastinal disorders | 75/763 | 17/378 | 21/352 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 74/763 | 29/378 | 11/352 |
| BronchitisInfections and infestations | 73/763 | 10/378 | 21/352 |
| Abdominal painGastrointestinal disorders | 64/763 | 7/378 | 9/352 |
Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.
| Age, Continuous(years) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| Mean | 45.3 ± 10.86 | 44.8 ± 10.77 | 45.1 ± 10.83 |
| Sex: Female, Male(Participants) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| Female | 140 | 65 | 205 |
| Male | 623 | 313 | 936 |
| Ethnicity (NIH/OMB)(Participants) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| Hispanic or Latino | 111 | 59 | 170 |
| Not Hispanic or Latino | 649 | 317 | 966 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 2 | 7 |
| Asian | 17 | 9 | 26 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 155 | 82 | 237 |
| White | 573 | 282 | 855 |
| More than one race | 5 | 1 | 6 |
| Unknown or Not Reported | 6 | 2 | 8 |
| Race/Ethnicity, Customized(Participants) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| Asian | 17 | 9 | 26 |
| Black or African American | 155 | 82 | 237 |
| Hispanic or Latino | 95 | 56 | 151 |
| Other | 20 | 6 | 26 |
| White Non-Hispanic | 476 | 225 | 701 |
| Region of Enrollment(Participants) | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | Control (Baseline to Switch) | Total |
|---|---|---|---|
| Belgium | 32 | 20 | 52 |
| Canada | 45 | 21 | 66 |
| France | 69 | 28 | 97 |
| Poland | 91 | 35 | 126 |
| Spain | 117 | 52 | 169 |
| Sweden | 23 | 5 | 28 |
| Switzerland | 26 | 13 | 39 |
| United Kingdom | 47 | 23 | 70 |
| United States | 313 | 181 | 494 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Feb 2017, 23 months.
Results were first posted in Nov 2018, 1 year 9 months after primary completion. A results delay was requested in Feb 2018.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 23 months is close to that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →